Nervous System Diseases

Symptoms and General Pathology

All Conditions

Neuralgia

Pain

Polyneuropathies

Peripheral Nervous System Diseases

Neuromuscular Diseases

Neurologic Manifestations

All Drugs and Chemicals

Flavonoid

Quercetin

Antioxidants

Protective Agents

Questionnaires completed at Baseline and at End of Study Visit.

Participants take Quercetin tablets by mouth 2 times every day for 12 weeks.

Questionnaires regarding quality of life, pain level, and related symptoms completed at Baseline and at End of Study Visit.. It should take less than 1 hour to complete these questionnaires.

Questionnaires

500 mg by mouth twice daily (after breakfast and dinner) for 12 weeks during study.

Salahadin Abdi, MD, PHD

The goal of this clinical research study is to learn about the effectiveness of quercetin in treating and preventing CINP. Researchers also want to learn if quercetin has an effect on participant's quality of life.

Study Product Administration:

If participant is found to be eligible to take part in this study, participant will take quercetin tablets by mouth 2 times every day for 12 weeks. The study staff will give participant the tablets and additional instructions on how to take the study product.

Length of Participation:

Participant may take quercetin for up to 12 weeks. Participant will no longer be able to take quercetin if the pain symptoms gets worse, if intolerable side effects occur, or if participant is unable to follow study directions.

Study Visits:

Every week, participant will either come to the clinic or a member of the staff will call participant to learn how participant is doing, if participant has had any side effects, and to check that participant is taking quercetin correctly. Participant will also complete a questionnaire about any pain symptoms participant may be having. The call/questionnaire should take about 10-15 minutes to complete.

End-of-Study Visit:

About 7 days after participant's last dose of quercetin, participant will complete the same questionnaires participant completed at screening.

Participation in this study will be over after the end-of-study visit.

This is an investigational study. Quercetin is commercially available as a supplement, but it is not FDA approved.The study doctor can explain how the study product is designed to work.

Up to 20 participants will be enrolled in this study. All will take part at MD Anderson.

Trial of Quercetin in the Treatment and Prevention of Chemotherapy-induced Neuropathic Pain in Cancer Patients

Prospective Open Labeled Pilot Trial of Quercetin in the Treatment and Prevention of Chemotherapy-induced Neuropathic Pain in Cancer Patients

Primary endpoint is the change in neuropathic pain intensity during 12 weeks of treatment using the the Douleur Neuropathique en 4 questions (DN4).

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Trial of Quercetin in the Treatment and Prevention of Chemotherapy-induced Neuropathic Pain in Cancer Patients	NCT02989129	Polyneuropathie... Chemotherapy In...	Questionnaires Quercetin	18 Years -	M.D. Anderson Cancer Center
Trial of Quercetin in the Treatment and Prevention of Chemotherapy-induced Neuropathic Pain in Cancer Patients	NCT02989129	Polyneuropathie... Chemotherapy In...	Questionnaires Quercetin	18 Years -	M.D. Anderson Cancer Center
Trial of Quercetin in the Treatment and Prevention of Chemotherapy-induced Neuropathic Pain in Cancer Patients	NCT02989129	Polyneuropathie... Chemotherapy In...	Questionnaires Quercetin	18 Years -	M.D. Anderson Cancer Center

Spots Global Cancer Trial Database for chemotherapy induced neuropathic pain